Literature DB >> 6162501

Characterization of the receptor mediating the antianaphylactic effects of beta-adrenoceptor agonists in human lung tissue in vitro.

P R Butchers, I F Skidmore, C J Vardey, A Wheeldon.   

Abstract

1 The rank order of potency of six beta-adrenoceptor agonists as inhibitors of the anaphylactic release of histamine from fragments of passively sensitized human lung in vitro was (--)-isoprenaline greater than (--) -adrenaline greater than (+/-)-salbutamol greater than (--)-noradrenaline greater than R0363 greater than H133/22. 2 The beta-adrenoceptor antagonists, propranolol, atenolol and H35/25, blocked the response to both (--)-isoprenaline and (+/-)-salbutamol competitively. Each antagonist gave similar pA2 values with both agonists. pA2 values were consistently at the high end of the range expected for interaction at a beta 2-adrenoceptor. 3 Practolol did not antagonize isoprenaline in a competitive manner but was a competitive antagonist of salbutamol with a pA2 at the high end of the range expected for interaction at a beta 2-adrenoceptor. 4 Data obtained with agonists are consistent with the receptor being of the beta 2-subtype. Data obtained with antagonists indicate a consistently higher affinity for the receptor than observed for the beta 2-subtype in other tissues but do not suggest a novel beta-adrenoceptor subtype on the mast cell of the human lung.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6162501      PMCID: PMC2044454          DOI: 10.1111/j.1476-5381.1980.tb10987.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  19 in total

1.  Selective blockade of adrenoceptive beta receptors in the heart.

Authors:  D Dunlop; R G Shanks
Journal:  Br J Pharmacol Chemother       Date:  1968-01

2.  Antagonism by beta-adrenoceptor blocking agents of the antianaphylactic effect of isoprenaline.

Authors:  E S Assem; H O Schild
Journal:  Br J Pharmacol       Date:  1971-08       Impact factor: 8.739

3.  Immunological release of histamine and slow reacting substance of anaphylaxis from human lung. II. Influence of cellular levels of cyclic AMP.

Authors:  R P Orange; M A Kaliner; P J Laraia; K F Austen
Journal:  Fed Proc       Date:  1971 Nov-Dec

4.  An analysis of selective beta receptor blockade.

Authors:  B Levy; B E Wilkenfeld
Journal:  Eur J Pharmacol       Date:  1969-02       Impact factor: 4.432

5.  Beta-adrenoceptors invloved in inhibition of histamine release from sensitized guinea-pig lung.

Authors:  E Malta; C Raper
Journal:  Eur J Pharmacol       Date:  1975-01       Impact factor: 4.432

6.  Selective inhibitor of slow reacting substance of anaphylaxis.

Authors:  J Augstein; J B Farmer; T B Lee; P Sheard; M L Tattersall
Journal:  Nat New Biol       Date:  1973-10-17

7.  A new type of cardioselective adrenoceptive blocking drug.

Authors:  A M Barrett; J Carter; J D Fitzgerald; R Hull; D Le Count
Journal:  Br J Pharmacol       Date:  1973-06       Impact factor: 8.739

8.  Differentiation of receptor systems activated by sympathomimetic amines.

Authors:  A M Lands; A Arnold; J P McAuliff; F P Luduena; T G Brown
Journal:  Nature       Date:  1967-05-06       Impact factor: 49.962

9.  Isoproterenol antagonism of cardioselective beta adrenergic receptor blocking agents: a comparative study of human and guinea-pig cardiac and bronchial beta adrenergic receptors.

Authors:  H H Harms
Journal:  J Pharmacol Exp Ther       Date:  1976-11       Impact factor: 4.030

10.  Immunological release of histamine and slow reacting substance of anaphylaxis from human lung.

Authors:  M Kaliner; R P Orange; K F Austen
Journal:  J Exp Med       Date:  1972-09-01       Impact factor: 14.307

View more
  23 in total

1.  The effect of selective phosphodiesterase 3 and 4 isoenzyme inhibitors and established anti-asthma drugs on inflammatory cell activation.

Authors:  K H Banner; E Moriggi; B Da Ros; G Schioppacassi; C Semeraro; C P Page
Journal:  Br J Pharmacol       Date:  1996-11       Impact factor: 8.739

Review 2.  Regulation of mast cells by beta-agonists.

Authors:  Peter Peachell
Journal:  Clin Rev Allergy Immunol       Date:  2006 Oct-Dec       Impact factor: 8.667

Review 3.  Pharmacological studies of pulmonary anaphylaxis in vitro: a review.

Authors:  P O Ogunbiyi; P Eyre
Journal:  Agents Actions       Date:  1985-12

Review 4.  Do beta-blockers really enhance the risk of anaphylaxis during immunotherapy?

Authors:  David M Lang
Journal:  Curr Allergy Asthma Rep       Date:  2008-03       Impact factor: 4.806

5.  Salmeterol: a potent and long-acting inhibitor of inflammatory mediator release from human lung.

Authors:  P R Butchers; C J Vardey; M Johnson
Journal:  Br J Pharmacol       Date:  1991-11       Impact factor: 8.739

6.  Effect of prednisolone and ketotifen on beta 2-adrenoceptors in asthmatic patients receiving beta 2-bronchodilators.

Authors:  O E Brodde; U Howe; S Egerszegi; N Konietzko; M C Michel
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

7.  Beta-blocker therapy and the risk of anaphylaxis.

Authors:  J H Toogood
Journal:  CMAJ       Date:  1987-10-01       Impact factor: 8.262

8.  Desensitisation of mast cell beta2-adrenoceptor-mediated responses by salmeterol and formoterol.

Authors:  Anne-Marie Scola; Lee K Chong; S Kim Suvarna; Russell Chess-Williams; Peter T Peachell
Journal:  Br J Pharmacol       Date:  2003-12-08       Impact factor: 8.739

Review 9.  Beta 2 adrenergic receptors in asthma: a current perspective.

Authors:  T R Bai
Journal:  Lung       Date:  1992       Impact factor: 2.584

10.  Inhibition by salmeterol of increased vascular permeability and granulocyte accumulation in guinea-pig lung and skin.

Authors:  C J Whelan; M Johnson
Journal:  Br J Pharmacol       Date:  1992-04       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.